Share-based Payment Arrangement, Expense of Rapport Therapeutics, Inc. from 30 Jun 2023 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rapport Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2023 to 30 Sep 2025.
  • Rapport Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,735,000, a 49% increase year-over-year.
  • Rapport Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $16,372,000.
  • Rapport Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $10,235,000, a 190% increase from 2023.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Rapport Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $16,372,000 $4,735,000 +$1,553,000 +49% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $14,819,000 $4,389,000 +$2,035,000 +86% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $12,784,000 $4,040,000 +$2,549,000 +171% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $10,235,000 $3,208,000 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $3,182,000 +$2,323,000 +270% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $2,354,000 +$1,409,000 +149% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $1,491,000 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q3 2023 $859,000 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $945,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2

Rapport Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $10,235,000 +$6,710,000 +190% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $3,525,000 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.